
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
The guidance provides recommendations for the development and quality information that should be included in NDA and ANDA applications.
On Nov. 20, 2019, FDA published
Source:






